Status:
UNKNOWN
Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool.
Lead Sponsor:
University Hospital Augsburg
Conditions:
Characteristics Disease
Metastatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
A prospective observational trial of patients with metastatic cancer of various entities which aims at both clarifying the significance of liquid biopsy and establishing a foundation for translational...
Detailed Description
ALPS is a prospective observational trial to assess liquid biopsy as diagnostic tool in patients with various metastatic neoplasms. Liquid biopsy will be correlated not only with the tissue biopsy, bu...
Eligibility Criteria
Inclusion
- Written informed consent
- Age ≥ 18 years
- Histopathologically confirmed metastatic or locally advanced cancer
- No curative treatment options, except for germ cell tumors
- Written Agreement to be followed up at Augsburg University Medical Center
- Signed written informed consent for the Biobank Augsburg (Biobank-A)
- Willing to undergo treatment according to standard of care
- Availability or anticipated availability of tumor tissue at time point of inclusion
- Anticipated life expectancy of at least 3 months at time point of trial inclusion
Exclusion
- Psychological condition that would preclude informed consent
- Additional tumor treatment between acquisition of tumor tissue and trial inclusion
Key Trial Info
Start Date :
March 29 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2025
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT05245136
Start Date
March 29 2021
End Date
April 1 2025
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Augsburg
Augsburg, Bavaria, Germany, 86156